Is Albemarle Corporation (ALB) overvalued or fairly valued?

MarketChacha shows Albemarle Corporation's valuation in context — a trailing P/E of about 33.7, a forward P/E of about 11.6, a price-to-book of about 2.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Albemarle Corporation's revenue?

Albemarle Corporation reported revenue of $5.1B for FY2025, with net profit of $-510.6M, per official filings.

What is the share price of Albemarle Corporation (ALB)?

Albemarle Corporation last traded at $133.99 (+2.7% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

Albemarle Corporation

ALB · NYSE · Materials · United States

Snapshot

TickerALB

ExchangeNYSE

SectorMaterials

IndustrySpecialty Chemicals

CountryUnited States

Employees7,800

HeadquartersCharlotte, United States

Websitewww.albemarle.com

Filings tracked22

About Albemarle Corporation

Albemarle Corporation provides energy storage solutions worldwide. It operates through three segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride for use in lithium batteries used in consumer electronics and electric vehicles; power grids and solar panels; high-performance greases; and specialty glass used in consumer appliances and electronics. The Specialties segment provides bromine and highly specialized lithium solutions for various industries, such as energy, mobility, connectivity, and health comprising fire safety compounds; bromine-based specialty chemical products, including elemental bromine, alkyl bromides, inorganic bromides, brominated powdered activated carbon, and various bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications, including airbag initiators. This segment also provides organic synthesis processes in the areas of steroid chemistry and vitamins, and various life science applications, as well as intermediates for the pharmaceutical industry; technical services, including handling and use of reactive lithium products; and recycling services for lithium-containing by-products. The Ketjen segment offers clean fuels technologies, including hydroprocessing catalysts together with isomerization and alkylation catalysts; fluidized catalytic cracking catalysts and additives; and performance catalyst solutions comprising organometallics and curatives. It serves the grid storage, automotive, aerospace, conventional energy, electronics, construction, agriculture and food, pharmaceuticals, and medical device industries. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Who owns it

Insiders0.2%
Institutions99.8%
Public & other0.0%

1,303 institutional holders

Ownership breakdown from public market data.

Top holders

Capital World Investors8.39%
Blackrock Inc.8.05%
Vanguard Capital Management LLC6.53%
Vanguard Portfolio Management LLC5.45%
State Street Corporation4.66%
Barclays Plc2.79%
Geode Capital Management, LLC2.65%
Morgan Stanley2.45%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 26.3 points over the period — profitability is trending down.

Net margin trend16.4% → -9.9%

Margin has compressed by about 26.3 points over the period — profitability is trending down.

Return on equity-5.4%

Latest ROE of -5.4% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.5B · EPS 2.14

Est. earnings growth +502.9%

Next fiscal year

Rev $6.4B · EPS 11.52

Est. earnings growth +0.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$5.1B

Net margin

-9.9%

ROE

-5.4%

Revenue CAGR (2y)

-26.9%

EPS (FY2025)

-5.76

Net profit (FY2025)

$-510.6M

Ask MarketChacha about ALB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$5.1B	$-510.6M	-5.76	-9.9%	-5.4%
FY2024	$5.4B	$-1.2B	-11.20	-21.9%	-11.8%
FY2023	$9.6B	$1.6B	13.36	16.4%	16.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.7B	$480.0M	3.52	27.5%
2026Q1	$1.4B	$319.1M	2.34	22.3%
2025Q3	$1.3B	$-160.7M	-1.72	-12.3%
2025Q2	$1.3B	$22.9M	-0.16	1.7%
2025Q1	$1.1B	$41.3M	0.00	3.8%
2024Q3	$1.4B	$-1.1B	-9.45	-78.9%
2024Q2	$1.4B	$-188.2M	-1.96	-13.2%
2024Q1	$1.4B	$2.4M	-0.08	0.2%
2023Q3	$2.3B	$302.5M	2.57	13.1%
2023Q2	$2.4B	$650.0M	5.52	27.4%
2023Q1	$2.6B	$1.2B	10.51	48.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC7/23/2026material
8-K — Executive/director change
SEC6/5/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/8/2026material
8-K — Results of operations, Exhibits
SEC5/6/2026material
10-Q filing
SEC5/6/2026
8-K — Executive/director change
SEC4/17/2026material
10-K/A filing
SEC3/31/2026
8-K — Material agreement, Exhibits
SEC3/25/2026material
8-K — Completion of acquisition/disposition, Reg FD disclosure, Other events, Exhibits
SEC3/6/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/4/2026material
8-K — Results of operations, Exhibits
SEC2/11/2026material
10-K filing
SEC2/11/2026

2025

8-K — Executive/director change
SEC12/12/2025material
8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Material agreement, Material impairment, Reg FD disclosure, Other events, Exhibits
SEC10/27/2025material
8-K — Executive/director change
SEC8/12/2025material
10-Q filing
SEC8/4/2025
8-K — Executive/director change
SEC8/4/2025material
8-K — Results of operations, Exhibits
SEC7/30/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.